Compare KB Financial Group, Inc. (KB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? KB Financial Group, Inc. trades at $116.03 (market cap $42.72B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: KB Financial Group, Inc. is far larger — about 8.8× Travere Therapeutics Inc. Common Stock's market cap, and KB Financial Group, Inc. pays a 2.73% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KB | TVTX | |
|---|---|---|
Market Cap | $42.72B | $4.88B |
Volume | 268,131 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $132.88 | $67.52 |
52-Week Low | $80.15 | $26.79 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $214.27T | $5.01B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $117.00, down 4.08% on the day, with bearish technical signals from moving averages. Fundamentally, the company shows strong profitability with 28.09% net income margin and consistent earnings beats, though valuation metrics like P/E of 9.65 suggest potential undervaluation. Recent news highlights institutional interest and positive momentum coverage from financial media.
The stock presents a value opportunity with attractive valuation ratios and solid earnings growth, but faces near-term technical headwinds and mixed analyst sentiment. Key risks include market volatility and execution challenges in the competitive banking sector, while institutional accumulation and strong South Korean market performance provide supportive tailwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
